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Abstract
Pediatric Crohn’s disease is a chronic auto inflammatory bowel disorder affecting children under the age of 17 years. A
putative etiopathogenesis of Crohn’s disease (CD) is associated with disregulation of immune response to antigens
commonly present in the gut microenvironment. Heat shock proteins (HSP) have been identified as ubiquitous antigens
with the ability to modulate inflammatory responses associated with several autoimmune diseases. The present study
tested the contribution of immune responses to HSP in the amplification of autoimmune inflammation in chronically
inflamed mucosa of pediatric CD patients. Colonic biopsies obtained from normal and CD mucosa were stimulated with
pairs of Pan HLA-DR binder HSP60-derived peptides (human/bacterial homologues). The modulation of RNA and protein
levels of induced proinflammatory cytokines were measured. We identified two epitopes capable of sustaining
proinflammatory responses, specifically TNFÆ and IFN induction, in the inflamed intestinal mucosa in CD patients. The
responses correlated positively with clinical and histological measurements of disease activity, thus suggesting a
contribution of immune responses to HSP in pediatric CD site-specific mucosal inflammation.
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Introduction
Crohn’s disease (CD) is a form of chronic auto-inflammatory
bowel disease (IBD) characterized by patchy involvement of the
intestinal tract. Although CD can involve any part of the intestine,
ileo-colonic involvement is most common [1,2]. Approximately 20–
30 percent of all CD patients are children. Childhood presentation
and subsequent treatment of CD may dramatically impact the
patient’s growth, development and overallqualityof life [1,3]. CD is
pathogenetically based on prolonged remitting/relapsing inflam-
mation of immune origin, which generates damage at local mucosal
sites and includes systemic involvement. Immunological, genetic
and environmental factors could stochastically overlap in triggering
and perpetuating the inflammatory processes [4]. This study
addresses the hypothesis that local inflammation is the outcome
of inappropriate immune responses to common environmental
stimuli, and that such responses contribute to disease activity
independently of the events that have triggered the disease [2,4,5].
Such antigens should be available within both the microbial flora
andthe targettissue,over-expressed at the site ofinflammation[6,7]
and strongly antigenic [8,9,10]. A growing body of work [8,11–14],
including our own published findings [15–17], implicate that heat
shock proteins (HSP) are among the antigens capable of sustaining
such immune/autoimmune inflammation.
We have demonstrated in various autoimmune diseases that
HSP-derived epitopes are capable of inducing and modulating
specific T-cell responses and that such modulation correlates with
disease activity [15,18,19]. CD constitutes an ideal disease model
to test this hypothesis, as it often presents with patchy intestinal
involvement [1,3], enabling us to compare inflamed and non-
inflamed areas within the same individual, at the same time point.
In the present study, we tested three pediatric populations - CD,
Ulcerative Colitis (UC) and normal healthy patient biopsies.
These patient groups were tested for immune responses to a
pool of HSP-derived peptides designed to be Pan HLA-DR
binders (in order to overcome variability in presentation due to
MHC polymorphisms). These peptides were engineered to be
T-cell epitopes to focus on T-cell-mediated responses. Mucosal
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7714biopsies from inflamed and non-inflamed areas (as well as control
patients without CD) were obtained and probed for production of
cytokines involved in modulation of the immune response.
Immunological data were correlated with clinical and histological
data pertaining to disease activity.
Results
HSP60/65 peptide selection
The selection of the HSP60/65-derived peptide was performed
using a mathematical algorithm as described in Sette et al. [20]. A
list of peptides predicted to be good Pan-DR binders was
generated. Affinity to 15 different HLA types was tested in
binding assays for four human/bacterial homologous peptide
pairs, including the ones described here [19]. Preliminary studies
showed that the pairs P1–P2 and P7–P8 (see Table 1) were the
most antigenic of the pool for pediatric CD patients (not shown).
Proinflammatory reactivity to HSP-derived peptides is
found in inflamed but not in normal mucosa in CD
patients, UC patients or healthy patients
To assess the presence of specific immune reactivity against
HSP-derived peptides, we analyzed biopsies of colonic mucosa
from pediatric patients with CD, UC or no inflammatory disease
by measuring cytokine mRNA levels using Quantitative Real-time
polymerase chain reaction (QRT-PCR). In preliminary experi-
ments, we were not able to extract sufficient T cells from the
biopsy to perform functional assays, given the small size and the
difficulty of obtaining multiple biopsies from the same pediatric
patients.
Hence, we relied on HSP-derived peptides which were designed
to be exclusively T-cell epitopes. We used such peptides as antigens
in cultures employing the whole biopsy with the assumption, backed
by published experience [16,19,21], that immune responses to these
T-cell epitopes would be T-cell driven. Operators were blinded to
the origin of the samples. We investigated whether the altered
immune response to HSP60 was confined to chronically inflamed
intestinal areas. Media alone served as the culture control. As
mentioned above, CD is an ideal model of disease where both types
of tissue, i.e. inflamed and normal, can be found in the same subject.
Biopsies were classified macroscopically at the time of collection,
and later analyzed microscopically by the pathologist for disease
classification and scoring.
CD patients showed a well-characterized individual repertoire
of proinflammatory immune reactivity against specific HSP60/65-
derived peptides as illustrated in Figure 1. This proinflammatory
Table 1. HPS60/65-derived peptides included in the study.
Name Species Accession Nu aa position aa sequence
P1 mycobacterium tuberculosis CAA17397.1 254–268 GEALSTLVVNKIRGT
P2 Homo sapiens AAH02676.1 280–294 GEALSTLVLNRLKVG
P7 mycobacterium tuberculosis CAA17397.1 507–521 IAGLFLTTEAVVADK
P8 Homo sapiens AAH02676.1 535–549 VASLLTTAEVVVTEI
Pan-DR binding motives are highlighted in bold underlined or bold italics when more than one Pan-DR-binding site is present. P1-P8 refers to the name give to the
chosen peptides, aa: amino-acid.
doi:10.1371/journal.pone.0007714.t001
Figure 1. Mucosal proinflammatory response to HSP60/65-derived peptides in abnormal mucosa in the CD patients. CD tissue (black
bars) and control tissue (open bars) were stimulated ex-vivo with P1, P2, P7 and P8. After 36 hours, the RNA from cultured biopsies was extracted to
determine cytokine gene expression by QRT-PCR and values were expressed as ddCT. Figure 1A represents the ddCT for TNFÆ and Figure 1B
represents the ddCT for IFN.* p ,0.05. Bars represent mean and SD of repeated tests.
doi:10.1371/journal.pone.0007714.g001
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inflammatory infiltrate is present (black bars) as assessed by
histological analysis. Reactivity was not detectable in the section of
the intestine where the inflammation is minimal or absent (white
bars). The inflamed tissue showed a specific immune reactivity
directed mainly toward P2 and P7 peptides when compared to the
non-inflamed tissue of the same patient group. Indeed, results
showed that ex-vivo cultures of inflamed colonic biopsies re-
stimulated with these peptides were able to consistently induce a
proinflammatory cytokine profile dominated by increased mRNA
levels of TNFÆ and IFN as measured by QRT-PCR (Figure 1).
The response in the CD patients to P2 and P7 for TNFÆ
production showed statistical significance in abnormal biopsies (P
0.0122 and 0.0129 respectively) (Figure 1A). As shown in
Figure 1B, we found that the human P2 and P7 peptides were
also able to significantly induce IFN in biopsy samples of CD
patients (P 0.0267 and 0.0212 respectively).
Proinflammatory reactivity to P2 and P7 peptides is
characteristically disease- and site-specific
Peripheral blood mononuclear cells (PBMC) from the CD
patients tested with the HSP-derived peptides had the same
responses as normal controls (not shown). A comparison of
patients with ulcerative colitis (UC) disease or healthy controls
showed no differences in the induction of proinflammatory
cytokines in response to stimulation with P2 and P7. However,
the UC patient group showed reactivity to a different group of
HSP-derived peptides (not shown). Disease-specific recognition
patterns for HSP-derived T-cell epitopes is a phenomenon we
have described in several autoimmune diseases and was confirmed
here [12,15–17].
Correlation of immunological response between
homolog peptide pairs
As mentioned above, the selected peptide pairs included in the
study originated from conserved regions of microbial HSP65 and
the corresponding human homolog as Pan-DR binding peptides
(Table 1). We performed a series of statistical correlations between
the proinflammatory responses induced by the homolog peptide
pairs to assess the concomitant presence of reactivity to the selected
peptide pairs, P1–P2 and P7–P8. We found a strong association
between P7 and P8 for the production of TNFÆ and IFN. Pearson
r-values were 0.7781 (P 0.0017) and 0.7615 (P 0.0025), respectively.
This correlation was maintained even when the calculated outliers
(enclosed in an open circle in Figure 2) were taken out of the
analysis. The calculated r-values without the outliers were 0.6798
(P 0.015) and 0.6582 (P 0.0200) for TNFÆ and IFN, respectively.
No correlation was identified between the pair P1–P2 under the
same statistical criteria (Figure 2).
Immune response to HSP60/65-derived peptide in
inflamed colonic mucosa are skewed toward an
inflammatory rather than a regulatory phenotype
The expression pattern of IL4, IL10 and TGFH mRNA levels
was analyzed following peptide-specific stimulation. None of the
peptides included in the study were able to induce statistically
significant differences in the expression level of IL4, IL10 and
TGFH when cytokines were analyzed individually. IL10 induction
between CD patients versus controls showed no statistically
significant differences between the groups, with P-values of
0.6767; 0.3891; 0.2718 and 0.9829 for P1, P2, P7 and P8,
respectively. Similarly, no statistical difference was found between
control and CD for the TGFH and IL4 induction (not shown).
The ratio between IL10 and TNFÆ resulting from HSP60-
derived peptides stimulation was determined to quantitatively
assess the balance between regulatory and inflammatory functions
in the intestinal mucosa of normal individuals versus CD patients.
Interestingly, the IL10/TNFÆ ratio between normal control and
CD groups were statistically significantly different for HSP60-
derived peptide stimulation with P1, P7 and P8. The P-values
obtained by comparison of the study populations were 0.0137,
0.0162 and 0.0406 for P1, P7 and P8, respectively. Conversely, no
statistically significant difference was found for P2, perhaps due to
the size of the standard deviation in the control group (Table 2).
Figure 2. Correlation of proinflammatory cytokine response
between HSP60/65-derived homolog pairs. Logarithmic values of
QRT-PCR results of each HSP60-derived pair were correlated using
Pearson correlation, n=13 and a 95% confidence interval. Circles
enclosing data points are shown to indicate the patient excluded, in
secondary analysis, to demonstrate that correlations are not due to
outliers.
doi:10.1371/journal.pone.0007714.g002
Table 2. IL10 to TNFÆ ratio deduced from epitope-specific
cytokine production of biopsies of control and CD patients.
IL10/TNFa ratio
Peptide Control (n=11) CD (n=12) P-value
P1 1.29 (1.26) 0.95 (0.95) *0.0137
P2 1.12 (17.68) 0.99 (0.76) 0.2345
P7 1.39 (2.07) 0.97 (1.26) *0.0162
P8 1.19 (2.19) 0.93 (0.50) *0.0406
Ratios are expressed as median (range) and P-values calculated by unpaired t-
test analysis between groups. Positive significant correlation is shown with *.
doi:10.1371/journal.pone.0007714.t002
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HSP-peptides correlate with disease activity
The Pediatric Crohn’s Disease Activity Index (PCDAI) [22] was
used as an objective clinical parameter to investigate a possible
pathogenic relevance for the proinflammatory responses to
HSP60/65 epitopes and determine whether there was a statistical
correlation between the induction of a proinflammatory response
by specific HSP60/65-derived peptides and disease severity.
Indeed, data analysis showed a statistical correlation between
PCDAI in CD patients with P2 and P7 peptide cytokine
production that proved to be relevant in the immunological
studies, i.e., the HSP60/65-derived peptide that triggered a
prevalent proinflammatory cytokine induction. As shown in
Figure 3, P2 showed a positive Pearson r-value of 0.6666 and
0.7227 for IFN and TNFÆ, respectively. P-values for these
correlations were also statistically significant, 0.0128 and 0.0053,
respectively. Similarly, peptide P7 revealed r- and P-values of
0.6992 and 0.0078, respectively, for TNFÆ while r- and P-values of
0.6346 and 0.0198 for IFN (Figure 3). No correlation was found
between proinflammatory response and disease duration. The
QRT-PCR results for TNFÆ and IFN for the P8 peptide
presented a high statistical correlation with PCDAI with Pearson
r-value of 0.7375 (P 0.0040) and 0.6887 (P 0.0092), respectively. P1
showed no correlation to disease activity.
Immunological proinflammatory responses to HSP-
peptides correlate with histologic data
In further support of the relevance of the correlations between
the immunological findings and the clinical picture, we performed
statistical correlations between the proinflammatory response
directed against the relevant HSP60-derived peptides and
histological scores of the biopsies.
A positive statistical correlation was found with P7 and P8
peptides when proinflammatory cytokine QRT-PCR values were
associated with histological score in CD. We used a Pearson
statistical correlation with all peptides and the individual histolog-
ical scores provided by the pathologist. Positive correlations of
0.7073 (P 0.0101) and 0.7714 (P 0.0033) for P7 were found when
histological score was compared to IFN and TNFÆ logarithmic
Induction Index, respectively. Similarly, positive correlations were
Figure 3. Correlation between immunological data and disease activity. Logarithmic values of QRT-PCR results were correlated with PCDAI
by using Pearson correlation. Left and right panels correspond to TNFÆ versus PCDAI and IFN versus PCDAI correlations, respectively.
doi:10.1371/journal.pone.0007714.g003
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(P 0.0245) for IFN and TNFÆ induction, respectively (Figure 4).
IFNc and TNFa are CD4 positive producing T cells in the
biopsies of inflamed CD mucosa
To validate the QRT-PCR data and to assess the contribution
of T cells to the local inflammatory process, immunohistochem-
istry was performed (Figure 5). Analysis of inflamed and normal
biopsies indicated that IFNc and TNFa producing cells were CD4
positive T cells with an increased amount of colocalization found
in inflamed tissue from patients with CD. In addition, inflamed
biopsies showed upregulation of IL23 and an abundance of
HSP60 expression in CD4 positive T cells. Only inflamed tissue
expressed IL17. IL-10 and FoxP3 expression was not detected in
the biopsies (data not shown).
Discussion
Despite of recent advances in the clinical understanding of CD,
important questions concerning the immunopathology of this
disease remain unanswered, particularly regarding the cause of
persistent gut inflammation. A commonly held view is that the
chronic inflammation is primarily the consequence of a disregulated
adaptive immune system leading to an immunological imbalance
with a resulting excess of proinflammatory cytokines [5,23,24].
Our working hypothesis aims to address the question of whether
the inflammation of colonic mucosa in pediatric CD is the result of
an inappropriate and self-perpetuating immune response to
endoluminal antigens, perhaps in association with overlapping
failures of the immunoregulatory mechanisms of inflammation
[25–27]. To perpetuate inflammation, such immune responses
should ideally be detectable at the site of mucosal inflammation
and directed toward antigens readily available and possibly over-
expressed at such sites [6,7,9]. Perpetuation of proinflammatory
responses could also be, at least in part, determined by cross
recognition of sequence motifs shared between self and exogenous
proteins [28–30]. This would be particularly important in the
context of a disease, such as CD, where there is an abundance of
exogenous antigens in direct contact with the inflamed tissues
[25,31,32]. The need to assess specificity of antigen recognition led
us to focus on adaptive immune responses of T cells. Consistent
with these postulates and our own previous work [16,17], we
evaluated immune responses to HSP and correlated such
responses with clinical and histological characteristics of the
disease. The scarcity of the samples due to the age of the subjects
and the consequent impossibility of obtaining enough purified T
cells posed a technical hurdle. Hence, we stimulated the whole
biopsy with peptides, which were designed and validated to be T-
cell-specific epitopes, to allow for the study of T-cell-specific
responses.
Figure 4. Correlation between immunological data and histology score. Logarithmic values of Induction Index were correlated with
histology score by using Pearson correlation. Left and right panels correspond to TNFÆ versus histology score and IFN versus histology correlations,
respectively.
doi:10.1371/journal.pone.0007714.g004
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homologue peptides derived from HSP60/65, which were
designed to be Pan HLA-DR binders to overcome inconsistencies
in immune responses determined by HLA polymorphism. This
method has proved to be very successful in identifying T-cell-
specific epitopes relevant to the immunopathogenesis of various
diseases [16,19]. The use of both inflamed and normal mucosa
from the same patients allowed efficient measurement of T-cell-
specific immune responses directly related to the inflammatory
process. This approach was effective in identifying molecular
signatures of immunological responses to HSP in CD and in
correlating them with disease activity and histological aspects of
inflammation. In fact, we found that two of the peptides tested,
namely P2 (human-derived) and P7 (bacterial-derived) induced a
significant increase in proinflammatory immune responses in CD
patients when compared to controls. This reactivity was not found
in samples from non-inflamed mucosa from the same CD patients,
UC patients and healthy controls. Furthermore, the same peptides
were unable to significantly induce TNFÆ and IFN in PBMC
from the same patients, which supports the idea that recognition is
restricted to the inflammation site. Hence, immune responses to
HSP60 epitopes are disease- and inflammation-specific. Proin-
flammatory immune responses to P2, P7 and P8 significantly
correlate with clinical and histological scores of disease activity.
These findings underscore the potential that abnormal immune
responses to HSP may affect the clinical relevance of the disease,
thus suggesting a direct pathogenic relationship. At least in this
series, proinflammatory immune responses did not correlate to
disease duration in the CD patients studied.
HSP responses in human autoimmunity are exceptionally
complex [10,33] and are likely the result of a dynamic balance
between self and non-self recognition in the context of apparently
contradictory proinflammatory and tolerogenic signals [14,34].
This network of immune responses is the consequence of the
abundance of peptides with significantly conserved sequence
homology at the site of inflammation. This homology can often
lead to cross reactivity between self and non-self proteins
[14,18,28–30]. In the case of CD, we found a significantly positive
correlation between human and microbial peptides for their ability
to induce proinflammatory responses, supporting the concept of
immune cross reactivity as one of the mechanisms fueling
inflammation. As we recently suggested [17], the complexity of
immune responses to HSP-derived peptides underscores the role in
which immunity to HSP plays in the pathogenesis of autoimmune
inflammation in various diseases, irrespective of the disease
triggers [12,19,35,36]. Indeed, the immunological responses of
proinflammatory epitopes in CD significantly correlate with
clinical and histological signs of active inflammation. The
human-derived peptide P2 responses can be directly classified as
autoimmune. The combination immune responses found with the
P7/P8 pair may be the result of overlapping mechanisms of cross
reactivity that perpetuate inflammation.
We could not find significant differences for IL10 induction
between controls and CD patients after peptide stimulation in
ex-vivo cultures of colonic biopsies; suggesting that at least at this
level, the regulatory cytokine profile is similar between groups.
However, the ratio of IL10/TNFÆ, which is commonly considered
an indicator of overall balance between inflammatory and
regulatory functions [19], was statistically different between
controls and CD for most of the tested peptides. Such a finding
suggests that a dysfunctional balance is present in the complex
regulatory mechanisms involved in the chronic inflammation seen
in CD. Indeed, it has been shown that clinical response to
infliximab in UC patients was correlated to reduction in TNFa
Figure 5. CD4 T cells produce TNFa, IFNc, IL23 and HSP 60.
Immunohistochemical analysis of inflamed CD sections shows the
colocalization of TNFa, IFNc, IL23 and HSP60 with CD4. CD4 FITC
(shown in green) and TNFÆ, IFNc, IL23, or HSP60 (shown in red) can be
detected in inflamed sections. Additionally, IL-17 (shown in green)
producing cells can be seen in inflamed sections. White arrows depict a
representative double labeled cell and red arrows depict a represen-
tative single labeled cell.
doi:10.1371/journal.pone.0007714.g005
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not that of IL10 and IL4 mRNA [37].
Immunohistochemistry confirmed an increase in the inflamed
versus noninflamed biopsies for the pro-inflammatory cytokines;
TNFÆ, IFN, IL17 and IL23. This upregulation was contributed
by CD4 positive cells, which were abundant in inflamed biopsies,
indicating specific CD4 T cell involvement in chronic inflamma-
tion of IBD.
In addition, inflamed biopsies showed an abundance of HSP60
expression, including in CD4 positive cells, confirming visually a
direct link between immunologically relevant cells and expression
of HSP in the presence of chronic inflammation. These data
confirm a plethora of reports supporting the upregulation and
immunodominant role for HSP in inflammation. This notion does
not necessarily collide, in our opinion with a recent report from
Hu et al. These investigators reported a decrease in HSP27 and
HSP70 expression in actively inflamed mucosa [38]. HSP27 and
HSP70 have different regulatory mechanisms than HSP60 (or
dnaJ); and in that specific study, their expression was not measured
in immune cells [38–40].
In summary, our data propose an epitope-specific contributor of
autoimmune inflammation in CD, define the dominant epitopes
and consequently may support a future translational approach
that, based on the possibility to design an epitope-specific
immunonotherapeutic intervention in pediatric CD patients,
could be an alternative treatment able to restore normal regulatory
immune functions [41] as seen in other autoimmune disease
models [42].
Materials and Methods
Patient population
Patients were recruited from the pediatric gastroenterology
outpatient and inpatient services at Children’s Hospital, San Diego.
Healthy patients and IBD patients undergoing colonoscopy for
varying routine indications were asked to participate in this study.
The Human Research Protection Programs of University of
California San Diego and Children’s Hospital of San Diego
approved consent forms were completed for each enrolled subject.
IBD Study Group: Inclusion criteria were children between 3–17
years of age, with IBD undergoing colonoscopy as part of their
initial or follow-up evaluation. Exclusion criteria were the evidence
of concurrent gastrointestinal infection, allergic colitis or any other
chronic disease involving the intestinal tract. Healthy Control
Group: Inclusion criteria were children undergoing colonoscopy for
specific gastrointestinal symptoms, but who were found to have
normal endoscopy and histology, anal fissures or single juvenile
polyp.
Study Subjects
No significant differences in age, gender or ethnicity were
detected in the patient population used. The study population was
composed as follows: 11 subjects in the healthy patient control, 13
in the CD and 13 in the UC group.
Clinical Procedure
All procedures were performed under general anesthesia by a
pediatric gastroenterologist. Biopsies were taken through the
Olympus PCF100 colonoscope (Melville, NY) using disposable
multiple sample biopsy forceps (Boston Scientific, Watertown, MA).
Disease activity index and Histology
In patients with CD, clinical disease activity was evaluated using
the Pediatric Crohn’s Disease Activity Index (PCDAI) [22] at
enrollment. For histological examination, colon biopsies were fixed
using standard processing on formalin-fixed paraffin embedded
tissue. Biopsy sections were stained with Hematoxylin 2 and Eosin
Y (Richard-Allan Scientific Kalamazoo, MI), according to
manufacturer’s instructions. Analyzed tissues were scored for the
degree of inflammation as follows: Acute inflammation (0 normal,
1 mild, 2 moderate and 3 severe); Chronic inflammation (0
normal, 1 mild, 2 moderate and 3 severe); Ulceration (0 present
and 1 absent); and Crypt abscesses (0 present and 1 absent). The
maximum histology score was 8. The pathologist was blinded to
patient’s clinical history.
Peptide selection
All HSP60/65-derived peptides were designed using a comput-
ing algorithm developed by Dr. Sette (LIAI, La Jolla, CA) [20] and
validated by using HLA-DR in binding assays [19]. All peptides
used in this study were HSP60/65-derived peptides (Synthetic
Biomolecules Inc., San Diego, CA) of 15 amino acid length
originated from the conserved regions of human and Mycobacterium
tuberculosis HSP60/65. Due to limitations of biopsy sample size,
only two sets of peptides were chosen for this study and are shown
in Table 1. Additionally, the P1/P2 and P7/P8 homolog pairs
were chosen due to their optimum Pan DR scores in the microbial
and human epitopes, respectively [19].
Biopsy stimulation
The operator, blinded to clinical and histological reports, per-
formed the peptide stimulation of biopsy sample in addition to
immunological analysis. Whenever possible, two sets of biopsies
per patient were obtained from endoscopically normal and
abnormal colonic mucosa at gross appearance. Biopsies were
washed once in fresh media; cultured directly in U-bottom 96-well
plate in a final volume of 200 Dl for 36 hours in complete media
(RPMI 1640, 10% heat-inactivated serum, Penicillin, streptomy-
cin, and L-Glutamine) in a 5% CO2 incubator at 37uC. Incu-
bation with HSP60/65-derived peptides was done at 10 mg/ml or
with phytohemagglutinin (PHA) at 2.5 mg/ml. Samples were
disrupted by adding Lysis buffer and frozen at 280uCu pt o1
month before RNA extraction.
Quantitative Real Time PCR assessment of cytokine
expression
Total RNA was extracted from biopsies incubated with either
media or HSP60/65-derived peptide. The total RNA was reverse
transcribed using Improm II Reverse Transcriptase strand
synthesis system (Promega, Madison, WI,) in a final volume of
20 mL. The relative amount of TNFÆ, IFN, IL10, TGFH and IL4
mRNA in each sample was normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Each measurement was
carried out in duplicate at the linear amplification range of the
QRT-PCR. Results were expressed as the ddCT of peptide
stimulation and media control. The forward and reverse primers
and probes (IDT, Coralville, IA) used for the PCR were as follows:
GAPDH, GeneBank Accession number (Acc. Nu) M33197: (212–
230), (259–280) and JOE (231–253) BHQ-1; IFN, Acc. Nu
NM_000619: (492–511), (546–567), JOE (518–542) BHQ-1; IL4
Acc. Nu NM_000589.2: (645–663), (692–710), FAM 59 (665–689)
BHQ-1; IL10, Acc. Nu NM_000572: (137–157), (186–206), FAM
59 (160–185) BHQ-1; TGFH1, Acc. Nu NM_000660.1: (1728–
1747), (1772–1789), TET (1749–1768) BHQ-1 and TNFÆ, Acc. Nu
NM_000594: (775–794), (826–843), FAM (796–820) BHQ-1,
respectively. Immunological analyses presented in the study were
performed blinded to clinical and histological reports.
HSP in Autoimmune Inflammation
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Formalin fixed and paraffin-embedded biopsies were used for
immunohistochemical analysis of TNFÆ, IFN, IL10, HSP60,
IL23 and CD4 (AbCam). 10 mM sections from both inflamed and
normal tissue biopsies were used from seven patients for analysis.
Briefly, sections were deparaffinized in xylene. The slides were
rinsed and antigen retrieval was performed using Dako target
retrieval solution for 30 minutes at 96uC. Sections were blocked
for two hours and stained with primary antibody for an additional
two hours. Slides were then incubated in fluorescent secondary
antibody from Invitrogen. Following three washes, slides were
coverslipped using Vectashield from Vector Laboratories and
viewed on a Zeiss confocal microscope.
Data Analysis
Statistical analysis was performed using GraphPad Prism
(GraphPad Software, San Diego CA). When necessary, a log
transformation was performed to obtain a normal distribution.
Parametric t-test was used for between-groups comparisons. In all
cases, log transformation was used at a confidence interval of 95%.
A P value of ,0.05 was considered significant. Two-tailed
evaluation was always applied for the statistical tests. Pearson
correlation coefficients were calculated to assess relationships
between Induction Index and PCDAI or Histologic score or in
between peptides.
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